Professor Dame Sally Davies, Chief Medical Officer for England and Chief Medical Adviser to the UK government, has reviewed evidence for the therapeutic benefit of cannabis-based medicinal products.

The review summarises the results of recent reviews and discusses the quality of evidence. Professor Davies concludes that cannabis-based medicinal products should be moved out of a Schedule 1 classification. Schedule 1 drugs by definition have little or no therapeutic potential.

This review forms part of a series of measures announced by the Home Secretary on 19 June 2018 looking at the scheduling of cannabis. Its conclusion signals the start of a second review, which will be led by the Advisory Council on the Misuse of Drugs ( ACMD ).